Neurofibroma differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) |
Sara Mohsin (talk | contribs) |
||
Line 23: | Line 23: | ||
|+Differentiating neurofibroma from other diseases | |+Differentiating neurofibroma from other diseases | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease entity | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease entity | ||
!Etiology (Genetic or others) | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological findings | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological findings | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Immunohistochemical staining | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Immunohistochemical staining | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Risk factors | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Risk factors | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Common site of involvement | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Common site of involvement | ||
!Clinical manifestations | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Other associated features | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Other associated features | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |'''Neurofibroma''' | | style="background:#DCDCDC;" align="center" + |'''Neurofibroma''' | ||
| | |||
| | | | ||
* Uniphasic, low to moderate cellularity | * Uniphasic, low to moderate cellularity | ||
Line 64: | Line 67: | ||
| | | | ||
* Can occur anywhere | * Can occur anywhere | ||
| | |||
| | | | ||
* Nerve often not identified, incorporates nerve, axons often present in lesion | * Nerve often not identified, incorporates nerve, axons often present in lesion | ||
Line 75: | Line 79: | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |'''Schwannoma''' | | style="background:#DCDCDC;" align="center" + |'''Schwannoma''' | ||
| | |||
| | | | ||
* Encapsulated | * Encapsulated | ||
Line 91: | Line 96: | ||
| | | | ||
* NF-2 associated | * NF-2 associated | ||
| | |||
| | | | ||
| | | | ||
Line 98: | Line 104: | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |'''Palisaded encapsulated neuroma''' | | style="background:#DCDCDC;" align="center" + |'''Palisaded encapsulated neuroma''' | ||
| | |||
| | | | ||
* Solitary | * Solitary | ||
Line 110: | Line 117: | ||
| | | | ||
* 90% lesions affect the face | * 90% lesions affect the face | ||
| | |||
| | | | ||
* No known familial association | * No known familial association | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |'''Traumatic neuroma''' | | style="background:#DCDCDC;" align="center" + |'''Traumatic neuroma''' | ||
| | |||
| | | | ||
* Numerous well formed small nerve twigs | * Numerous well formed small nerve twigs | ||
Line 121: | Line 130: | ||
| | | | ||
* History of trauma or surgery | * History of trauma or surgery | ||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |'''Neurotized Melanocytic Nevus''' | | style="background:#DCDCDC;" align="center" + |'''Neurotized Melanocytic Nevus''' | ||
| | |||
| | | | ||
* Superficial classic nevoid [[melanocytes]] | * Superficial classic nevoid [[melanocytes]] | ||
Line 135: | Line 146: | ||
Negative for: | Negative for: | ||
* Factor XIIIa | * Factor XIIIa | ||
| | |||
| | | | ||
| | | | ||
Line 140: | Line 152: | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |'''Cutaneous Myxoma (Superficial angiomyxoma)''' | | style="background:#DCDCDC;" align="center" + |'''Cutaneous Myxoma (Superficial angiomyxoma)''' | ||
| | |||
| | | | ||
* [[Spindle]] to stellate cells with oval nuclei | * [[Spindle]] to stellate cells with oval nuclei | ||
Line 148: | Line 161: | ||
| | | | ||
* Associated with Carney complex | * Associated with Carney complex | ||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |'''Nerve sheath myxoma''' | | style="background:#DCDCDC;" align="center" + |'''Nerve sheath myxoma''' | ||
| | |||
| | | | ||
* Markedly hypocellular with abundant [[mucopolysaccharides]] | * Markedly hypocellular with abundant [[mucopolysaccharides]] | ||
Line 157: | Line 172: | ||
|Positive for: | |Positive for: | ||
* [[S100|S-100]] | * [[S100|S-100]] | ||
| | |||
| | | | ||
| | | | ||
Line 162: | Line 178: | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |'''Malignant peripheral nerve sheath tumor''' | | style="background:#DCDCDC;" align="center" + |'''Malignant peripheral nerve sheath tumor''' | ||
| | |||
| | | | ||
* Generalized atypia | * Generalized atypia | ||
Line 168: | Line 185: | ||
|Positive for: | |Positive for: | ||
* [[S100|S-100]] (30%) | * [[S100|S-100]] (30%) | ||
| | |||
| | | | ||
| | | | ||
Line 173: | Line 191: | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |'''Dermatofibrosarcoma protuberans (DFSP)''' | | style="background:#DCDCDC;" align="center" + |'''Dermatofibrosarcoma protuberans (DFSP)''' | ||
| | |||
| | | | ||
* More cellular | * More cellular | ||
Line 184: | Line 203: | ||
| | | | ||
* Deep soft tissue of posterior neck | * Deep soft tissue of posterior neck | ||
| | |||
| | | | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |'''Spindle cell lipoma''' | | style="background:#DCDCDC;" align="center" + |'''Spindle cell lipoma''' | ||
| | |||
| | | | ||
* Delicate encapsulation | * Delicate encapsulation | ||
Line 195: | Line 216: | ||
* CD34 (strongly) | * CD34 (strongly) | ||
* [[S-100]](stains only fat cells) | * [[S-100]](stains only fat cells) | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
|style="background:#DCDCDC;" align="center" + |'''Ganglioneuroma''' | | style="background:#DCDCDC;" align="center" + |'''Ganglioneuroma''' | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 206: | Line 230: | ||
| | | | ||
|- | |- | ||
|style="background:#DCDCDC;" align="center" + |'''Myxoid liposarcoma''' | | style="background:#DCDCDC;" align="center" + |'''Myxoid liposarcoma''' | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 213: | Line 239: | ||
| | | | ||
|- | |- | ||
|style="background:#DCDCDC;" align="center" + |'''Leiomyoma''' | | style="background:#DCDCDC;" align="center" + |'''Leiomyoma''' | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 220: | Line 248: | ||
| | | | ||
|- | |- | ||
|style="background:#DCDCDC;" align="center" + |'''Inflammatory myofibroblastic tumor''' | | style="background:#DCDCDC;" align="center" + |'''Inflammatory myofibroblastic tumor''' | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 227: | Line 257: | ||
| | | | ||
|- | |- | ||
|style="background:#DCDCDC;" align="center" + |'''Acrochorda''' | | style="background:#DCDCDC;" align="center" + |'''Acrochorda''' | ||
| | |||
| | |||
| | | | ||
| | | |
Revision as of 15:51, 22 April 2019
Neurofibroma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Neurofibroma differential diagnosis On the Web |
American Roentgen Ray Society Images of Neurofibroma differential diagnosis |
Risk calculators and risk factors for Neurofibroma differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2] Shanshan Cen, M.D. [3]
Overview
Neurofibroma must be differentiated from schwannoma, dermatofibrosarcoma protuberans (DFSP), ganglioneuroma, and melanocytic nevus.
Differential Diagnosis
Neurofibroma must be differentiated from:[1][2][3]
- Schwannoma
- Dermatofibrosarcoma protuberans (DFSP)
- Ganglioneuroma
- Dermal neurotized melanocytic nevus
- Myxoid liposarcoma
- Solitary circumscribed neuroma (palisaded encapsulated neuroma)
- Traumatic neuroma
- Superficial angiomyxoma
- Nerve sheath myxoma
- Malignant peripheral nerve sheath tumor (MPNST): has marked atypia and increased mitotic activity, may have necrosis
- Spindle cell lipoma
- Leiomyoma: has cigar-shaped nuclei, S100 negative, positive for smooth muscle actin and desmin
- Inflammatory myofibroblastic tumor: reactive spindle cells in inflammatory background
- Acrochorda (aka skin tag or soft fibroma)
Disease entity | Etiology (Genetic or others) | Histopathological findings | Immunohistochemical staining | Risk factors | Common site of involvement | Clinical manifestations | Other associated features |
---|---|---|---|---|---|---|---|
Neurofibroma |
Neurofibroma with degenerative atypia ("ancient change") has following microscopic features:
|
Positive for:
|
|
|
| ||
Schwannoma |
|
Positive for:
|
|
| |||
Palisaded encapsulated neuroma |
|
Positive for:
Negative for: |
|
| |||
Traumatic neuroma |
|
|
|||||
Neurotized Melanocytic Nevus |
|
Positive for:
Negative for:
|
|||||
Cutaneous Myxoma (Superficial angiomyxoma) |
|
Positive for: |
|
||||
Nerve sheath myxoma |
|
Positive for: | |||||
Malignant peripheral nerve sheath tumor |
|
Positive for:
|
|||||
Dermatofibrosarcoma protuberans (DFSP) |
|
Strongly positive for:
Negative for: |
|
||||
Spindle cell lipoma |
|
Positive for:
|
|||||
Ganglioneuroma | |||||||
Myxoid liposarcoma | |||||||
Leiomyoma | |||||||
Inflammatory myofibroblastic tumor | |||||||
Acrochorda |
References
- ↑ Neurofibroma. Libre Pathology 2015. http://librepathology.org/wiki/index.php/Neurofibroma#cite_note-pmid15486243-2 Accessed on November 17, 2015
- ↑ http://surgpathcriteria.stanford.edu/peripheral-nerve/neurofibroma/
- ↑ http://surgpathcriteria.stanford.edu/peripheral-nerve/neurofibroma/